Estée Lauder’s Digital Makeover: How CEO Stéphane de La Faverie Is Redrawing The Beauty Map!
Stock Market Today: Stocks Surge as S&P 500 and Nasdaq Hit Record Highs on Earnings and Trade Optimism
U.S. stocks rose on Friday, with the S&P 500 marking its fifth consecutive record and the Nasdaq Composite reaching an all-time high.
Google’s AI Investments Pay Off: How Billions in Spending Are Driving Growth
Stock Market Today: Mixed Trading as Wall Street Digests Tech Earnings and Trade Deal Hopes
Datadog Eyes $1 Billion Deal With Upwind: What’s At Stake & What Could Be Gained
Business & Market Movers
Estée Lauder’s Digital Makeover: How CEO Stéphane de La Faverie Is Redrawing The Beauty Map!
·Jul 25, 2025
Chevron’s $53 Billion Triumph Over Exxon: The Hess Acquisition Can Truly Reshape Big Oil!
·Jul 25, 2025
SentinelOne Soars: Could Palo Alto Networks Be Ready To Strike A $7 Billion Cybersecurity Deal?
·Jul 24, 2025Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023
Deep Dive & Research
Healthcare & Biotech
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?
Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning the impending blow from the loss of exclusivity on its cancer drug Keytruda.
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
DexCom’s Bold Type 2 Bet Could Reshape The Glucose Monitoring Market—What It Means for Investors!
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story
Tech & Energy
SentinelOne Soars: Could Palo Alto Networks Be Ready To Strike A $7 Billion Cybersecurity Deal?
SentinelOne’s stock spiked nearly 18% before paring gains following reports that Palo Alto Networks may be in advanced discussions to acquire the AI-driven cybersecurity firm.
Stock Market Today: US Stocks Hover Near All-Time Highs Amid Retail Sales Rebound and Earnings Reports
OraSure’s Turning Point: Why Serial Deal-Maker Ron Zwanziger Tried (Again) to Take It Over
Alphabet’s Dominance Under Fire: Is OpenAI’s New Browser The Biggest Threat To Google Search Yet?
AES Draws Buyout Buzz: Brookfield & BlackRock Could Spark One Of The Biggest Energy LBOs Ever
